Morgan Stanley Reiterates Overweight on Karuna Therapeutics, Maintains $280 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung has reiterated an Overweight rating on Karuna Therapeutics (NASDAQ:KRTX) and maintained a price target of $280.
August 04, 2023 | 6:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has reiterated an Overweight rating on Karuna Therapeutics and maintained a price target of $280.
The Overweight rating from Morgan Stanley indicates a positive outlook for Karuna Therapeutics. The maintained price target of $280 suggests that the analyst believes the stock has potential for significant upside. This could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100